Compare Gartner Inc (IT) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gartner Inc vs TransMedics Group Inc — how do they compare? Gartner Inc trades at $191.54 (market cap $12.34B), while TransMedics Group Inc trades at $78.41 (market cap $2.74B). The key difference: Gartner Inc is far larger — about 4.5× TransMedics Group Inc's market cap, and Gartner Inc is trading nearer its 52-week high, TransMedics Group Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Gartner Inc for 64 Days and TransMedics Group Inc for 24 Days on average.
| IT | TMDX | |
|---|---|---|
Market Cap | $12.34B | $2.74B |
Volume | 919,809 | 949,331 |
Sector | Technology | Health |
52-Week High | $258.17 | $150.42 |
52-Week Low | $125.68 | $61.99 |
Typical Hold Time | 64 Days | 24 Days |
Enterprise Value | $14.08B | $3.13B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gartner (IT) trades at $191.02, up 2.83% with a bullish technical signal. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Financials show strong profitability with a 69.63% gross margin and 113.58% ROE, though net income declined in 2025. Recent news highlights AI advisory demand and Gartner's industry leadership, driving positive sentiment.
Outlook remains supported by robust contract value and AI-driven consulting growth, but risks include a high P/B ratio of 160.06 and a shareholder investigation. Analyst consensus is mixed with a $174.63 price target below the current price, suggesting caution despite bullish technicals.
TransMedics Group (TMDX) trades at $78.17, down 3.58% on the day, with a bearish technical signal and mixed earnings history. The company reported strong 2025 results with $605.49M revenue and $190.29M net income, but 2026 projections show margin compression. Recent news highlights insider buying and leadership changes alongside legal investigations into fiduciary duties, creating a complex sentiment backdrop.
The stock offers growth potential with a consensus price target of $99.75, but faces risks from earnings misses, margin pressure, and ongoing legal scrutiny. Analyst consensus remains bullish with 69% buy ratings, yet investors must weigh robust profitability metrics against execution and regulatory uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gartner Inc
Based in Stamford, Conn., Gartner provides independent research and analysis on information technology and other related technology industries. Its research is delivered to clients' desktops in the form of reports, briefings, and updates. Typical clients are chief information officers and other business executives who help plan companies' IT budgets. Gartner also provides consulting services and hosted nearly 80 IT conferences across the globe in 2007.
Read more on IT →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
